Thu, Nov 21, 2024
[Archive]
Volume 29, Issue 136 (September & October 2021)
J Adv Med Biomed Res 2021, 29(136): 257-262 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mirzae M, Abbasi M H, Shahidi G A, Hosseinifakhr Q, Sina F, Habibi S A. Diabetes Increases the Incidence of Levodopa-Induced Dyskinesia in Parkinson’s Disease; A Case-Control Study. J Adv Med Biomed Res 2021; 29 (136) :257-262
URL: http://journal.zums.ac.ir/article-1-6163-en.html
URL: http://journal.zums.ac.ir/article-1-6163-en.html
Marzieh Mirzae1 
, Mohammad Hossein Abbasi1 , Gholam Ali Shahidi1 , Qodsiye Hosseinifakhr2 , Farzad Sina1 , Seyed Amirhassan Habibi * 3
, Mohammad Hossein Abbasi1 , Gholam Ali Shahidi1 , Qodsiye Hosseinifakhr2 , Farzad Sina1 , Seyed Amirhassan Habibi * 3
1- Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran
2- Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran
3- Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran ,Habibi.sah@iums.ac.ir
2- Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran
3- Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran ,
Abstract: (131691 Views)
Background and Objective: Dyskinesia is a debilitating complication of Parkinson's disease (PD), which appears due to some known risk factors. The effect of diabetes and high plasma glucose on the manifestation of dyskinesia has been evaluated in just a few previous reports. The current study aimed to assess the mentioned correlation.
Materials and Methods: In this case-control study, 88 patients with PD were enrolled and categorized into two equal groups of diabetic and non-diabetic patients. They were selected from the movement disorder clinic in Rasoul Akram Hospital, Tehran, Iran. Patients were evaluated regarding the presence of dyskinesia and its characteristics, besides the assessment of other clinical parameters.
Results: The prevalence of dyskinesia in diabetics, compared to non-diabetics, showed a higher rate (P=0.033). Baseline parameter equality was confirmed to exclude the confounding bias effect. Simultaneous involvement of upper and lower extremities (right after drug intake) was the most prevalent sign of dyskensia in diabetic patients with PD.
Conclusion: The comorbidity of PD and diabetes showed a higher prevalence of levodopa-induced dyskinesia (LID) in PD; this result was obtained based on homogeneity of the two groups in manners of age, disease, treatment duration and the dosage of levodopa.
Full-Text [PDF 479 kb]
(142100 Downloads)
| | Full-Text (HTML) (2244 Views)
✅ The comorbidity of PD and diabetes showed a higher prevalence of levodopa-induced dyskinesia (LID) in PD; this result was obtained based on homogeneity of the two groups in manners of age, disease, treatment duration and the dosage of levodopa.
Type of Study: Original Article |
Subject:
Clinical medicine
Received: 2020/08/10 | Accepted: 2021/03/14 | Published: 2021/04/4
Received: 2020/08/10 | Accepted: 2021/03/14 | Published: 2021/04/4
References
1. Taghizadeh G, Martinez-Martin P, Fereshtehnejad SM, Habibi SA, Nikbakht N, Alizadeh NH, Salehi S, Mehdizadeh M. Psychometric properties of the Berg balance scale in idiopathic Parkinson’disease in the drug off-phase. Neurological Sciences. 2018 Dec 1;39(12):2175-81. [DOI:10.1007/s10072-018-3570-4]
2. Mehdizadeh M, Lajevardi L, Hassan Habibi SA,et al. The association between fear of falling and quality of life for balance impairments based on hip and ankle strategies in the drug on-and off-phase of patients with idiopathic Parkinson'disease. Med J Islam Repub Iran. 2016. 30: 453.
3. Mehdizadeh M, Martinez-Martin P, Habibi SA, et al., The association of balance, fear of falling, and daily activities with drug phases and severity of disease in patients with Parkinson. Basic Clin Neurosci. 2019. 10(4): 355. [DOI:10.32598/bcn.9.10.295]
4. Marras C, Beck J , Bower J, et al. Prevalence of Parkinson's disease across North America. NPJ Parkinson's Disease. 2018; 4(1): 1-7. [DOI:10.1038/s41531-018-0058-0]
5. Levy G, Louis E, Mejia-Santana H, et al., Lack of familial aggregation of Parkinson disease and Alzheimer disease. Arch Neurol. 2004; 61(7): 1033-39. [DOI:10.1001/archneur.61.7.1033]
6. Sun Y, Chang Y, Chen H, Su Y, Fang Su H, Yi Li C. Risk of Parkinson disease onset in patients with diabetes: a 9-year population-based cohort study with age and sex stratifications. Diabetes Care. 2012. 35(5): 1047-49. [DOI:10.2337/dc11-1511]
7. Zhu F, Li C , Gong J , Zhu W , Gu L , Li N. The risk of Parkinson's disease in inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis. 2019. 51(1): 38-42. [DOI:10.1016/j.dld.2018.09.017]
8. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgraduate Med J. 2007. 83(980): 384-88. [DOI:10.1136/pgmj.2006.054759]
9. Tolosa E. Advances in the pharmacological management of Parkinson disease, in Neuropsychopharmacology. 2003, Springer. 65-78. [DOI:10.1007/978-3-7091-6020-6_4]
10. Huh E, Choi J, Sim Y, Sook Oh M. An integrative approach to treat parkinson's disease: ukgansan complements L-Dopa ameliorating dopaminergic neuronal damage and L-Dopa-induced dyskinesia in mice. Front Aging Neurosci. 2019. 10: 431. [DOI:10.3389/fnagi.2018.00431]
11. Sandyk R. The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci, 1993. 69(1-4): 125-30. [DOI:10.3109/00207459309003322]
12. Xu Q, Park Y, Huang X ,et al. Diabetes and risk of Parkinson's disease. Diabetes Care. 2011; 34(4): 910-15. [DOI:10.2337/dc10-1922]
13. Yang Y, Hsieh T, Li C, et al., Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine. 2017. 96(3): e5921 [DOI:10.1097/MD.0000000000005921]
14. Yue X, Li H, Yan H, Zhang P, Chang L, Li T. Risk of Parkinson disease in diabetes mellitus: an updated meta-analysis of population-based cohort studies. Medicine. 2016; 95(18): e3549 [DOI:10.1097/MD.0000000000003549]
15. Schernhammer E, Hansen J, Rugbjerg K, Wermuth L, Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes care. 2011; 34(5): 1102-08. [DOI:10.2337/dc10-1333]
16. Kotagal V, Albin R, Müller M, Koeppe R, Frey K, Bohnen N. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disorder. 2013. 19(5): 522-26. [DOI:10.1016/j.parkreldis.2013.01.016]
17. Taghizadeh G, Martinez-Martin P , Meimandi M, et al. Barthel index and modified rankin scale: psychometric properties during medication phases in idiopathic Parkinson disease. Ann Phys Rehabil Med. 2019. [DOI:10.1016/j.rehab.2019.08.006]
18. Mehdizadeh M, Martinez-Martin P, Habibi SA, Fereshtehnejad SM, Abasi A, Niazi Khatoon J, Saneii SH, Taghizadeh G. Reliability and validity of Fall Efficacy Scale-International in people with Parkinson’s disease during on-and off-drug phases. Parkinson’s Disease. 2019 [DOI:10.1155/2019/6505232]
19. Mehdizadeh M, Fereshtehnejad SM , Goudarzi S, et al., Validity and reliability of short-form McGill pain questionnaire-2 (SF-MPQ-2) in Iranian people with Parkinson's disease. Parkinsons Dis. 2020. 2020: 2793945 [DOI:10.1155/2020/2793945]
20. Mehdizadeh M, Mehraban A, Zahediyannasab R. The effect of group-based occupational therapy on performance and satisfaction of stroke survivors: pilot trail, neuro-occupational view. Basic Clin Neurosci. 2017. 8(1): 69. [DOI:10.15412/J.BCN.03080109]
21. Caligiuri M.P, Jeste D. Association of diabetes with dyskinesia in older psychosis patients. Psychopharmacol. 2004. 176(3-4): 281-86. [DOI:10.1007/s00213-004-1893-8]
22. Lévy E, Margolese H, Annable L, Chouinard G. Diabetes, tardive dyskinesia, parkinsonism, and akathisia in schizophrenia: a retrospective study applying 1998 diabetes health care guidelines to antipsychotic use. Can J Psychiatry. 2004. 49(6): 398-402. [DOI:10.1177/070674370404900611]
23. Ganzini L, Casey D, Hoffman W, Heintz R. Tardive dyskinesia and diabetes mellitus. Psychopharmacol Bull. 1992. 28(3): 281-86.
24. Lieberman JA, Alvir J. Diabetes and development of tardive dyskinesia. Am J Psychiatr. 1993. 1(50): 967.
25. Raja M, Azzoni A. Diabetes is not a risk factor for tardive dyskinesia: a retrospective observational study. Human Psychopharmacol. 2002. 17(1): 61-63. [DOI:10.1002/hup.354]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
